int j mol sci int j mol sci ijms international journal of molecular sciences 1422 - 0067 mdpi 26340618 4613227 10.3390 / ijms160920704 ijms - 16 - 20704 review mitochondria : a therapeutic target for parkinson 's disease ?
luo yu 1 * hoffer alan 1 hoffer barry 1 qi xin 2 * ross jaime m. academic editor coppotelli giuseppe academic editor 1 department of neurological surgery , case western reserve university , cleveland , oh 44106 , usa ; e - mails : alan.hoffer @ uhhospitals.org ( a.h. ) ; bhoffer @ intra.nida.nih.gov ( b.h . )
2 department of physiology , case western reserve university , cleveland , oh 44106 , usa * authors to whom correspondence should be addressed ; e - mails : yxl710 @ case.edu ( y.l. ) ; xxq38 @ case.edu ( x.q. ) ; tel. : + 1 - 216 - 368 - 4169 ( y.l. ) ; + 1 - 216 - 368 - 4459 ( x.q. ) .
01 9 2015 9 2015 16 9 20704 20730 10 6 2015 20 8 2015 ( c ) 2015 by the authors ; licensee mdpi , basel , switzerland .
2015 this article is an open access article distributed under the terms and conditions of the creative commons attribution license ( http :// creativecommons.org / licenses / by / 4.0 /) .
parkinson 's disease ( pd ) is one of the most common neurodegenerative disorders .
the exact causes of neuronal damage are unknown , but mounting evidence indicates that mitochondrial - mediated pathways contribute to the underlying mechanisms of dopaminergic neuronal cell death both in pd patients and in pd animal models .
mitochondria are organized in a highly dynamic tubular network that is continuously reshaped by opposing processes of fusion and fission .
defects in either fusion or fission , leading to mitochondrial fragmentation , limit mitochondrial motility , decrease energy production and increase oxidative stress , thereby promoting cell dysfunction and death .
thus , the regulation of mitochondrial dynamics processes , such as fusion , fission and mitophagy , represents important mechanisms controlling neuronal cell fate .
in this review , we summarize some of the recent evidence supporting that impairment of mitochondrial dynamics , mitophagy and mitochondrial import occurs in cellular and animal pd models and disruption of these processes is a contributing mechanism to cell death in dopaminergic neurons .
we also summarize mitochondria - targeting therapeutics in models of pd , proposing that modulation of mitochondrial impairment might be beneficial for drug development toward treatment of pd. parkinson 's disease mitochondrial dysfunction mitochondrial dynamics 1 .
introduction parkinson 's disease ( pd ) is the second most common neurodegenerative disorder after alzheimer 's disease , affecting over 1 % of the population older than 60 years of age .
clinically , it is diagnosed primarily based on motor abnormalities including bradykinesia , resting tremor , and cogwheel rigidity [ 1 ] .
a key characteristic of pathology in pd is the degeneration of the nigrostriatal ( ns ) dopaminergic pathway which is one of the most important dopamine ( da ) pathways in the brain and contains about 80 % of the total brain da. despite a large number of studies on the pathogenesis of pd , there is still inconclusive evidence about why dopaminergic neurons are selectively degenerated .
currently , there is no effective restorative treatment available for pd , only symptomatic treatment is available .
among a number of proposed mechanisms involved in pd pathogenesis , mitochondrial dysfunction has been repeatedly implicated as the cause of the death of da neurons in pd [ 2,3,4,5 ] .
mitochondria are critical for many cellular functions , such as intermediary metabolism [ 6,7 ] , redox signaling [ 8 ] , calcium homeostasis [ 9,10,11 ] , cell proliferation [ 12,13 ] , development [ 14,15 ] and cell death [ 16,17,18 ] .
mitochondrial dysfunction is mainly characterized by the generation of reactive oxygen species ( ros ) , a defect in mitochondrial electron transport complex enzyme activities , atp depletion , caspase 3 release and depletion of mitochondrial dna .
in this review , we summarize evidence on the critical involvement of mitochondria in both genetic mutation and environmental toxin - induced pd. we propose a causal role for mitochondrial dysfunction in the development of pd , because ( 1 ) neurotoxins causing parkinsonism , such as 1 - methyl - 4 - phenyl - 1,2,3,6 - tetrahydropyridine ( mptp ) , rotenone , paraquat , induce dopaminergic neuronal death through direct inhibition of mitochondrial complex i activity ; ( 2 ) mutant proteins from pd - related genes associate with mitochondria where they elicit diverse mitochondrial dysregulation and subsequently cause neuronal degeneration ; ( 3 ) therapeutic agents that target mitochondrial protein or inhibit mitochondrial damage can reduce neuropathological phenotypes of pd in animal models and cells from pd patients .
2. mitochondrial dysfunction in parkinson 's disease aberrant mitochondrial function is one of the major cytopathologies in pd and has been widely accepted as a central pathogenic mechanism underlying pd pathogenesis .
chronic systemic administration of rotenone , a specific complex i inhibitor and a pesticide , results in neuropathologic and behavioral changes in rats that are similar to human pd [ 19,20 ] .
1 - methyl - 4 - phenyl - 1,2,3,6 - tetrahydropyridine ( mptp ) , a meperidine analog found to cause parkinsonism in humans , exerts its toxic effects through metabolism to 1 - methyl - 4 - phenylpyridinium ( mpp +) , another complex i inhibitor [ 19,21 ] .
these compounds have long been used in animal models of pd. furthermore a number of familial forms of pd are associated with mutations in genes encoding both mitochondrially targeted proteins and proteins involved in mitochondrial function and / or oxidative stress responses , including mutations in pink - 1 , dj - 1 , parkin , and leucine - rich repeat kinase 2 ( lrrk2 ) [ 22 ] .
interestingly , one study reported that the size of mitochondria in dopaminergic neurons in the substantia nigra ( sn ; susceptible to pd degeneration ) is smaller than in neighboring non - dopaminergic neurons or in dopaminergic neurons of the ventral tegmental area which is more resistant in pd , suggesting a basis for the increased vulnerability of sn neurons to subtle changes in mitochondrial maintenance and function [ 23 ] .
in addition , increased oxidative stress due to mitochondrial compromise in pd model animals has been proposed to contribute to the degeneration of dopaminergic neurons [ 23 ] .
consistent with the evidence from basic science , clinical studies also showed that mitochondrial damage plays a predominant role in the development of pd in patients .
mild deficiency in mitochondrial respiratory electron transport chain nadh dehydrogenase ( complex i ) activity has been reported in the substantia nigra [ 24 ] as well as platelets [ 25,26 ] and lymphocytes [ 27,28 ] in pd patients , suggesting a systemic inhibition of complex i activity in pd patients .
mitochondrial dysfunction could lead to increased oxidative stress .
indeed oxidative damage to lipids , proteins and dna has been detected in brain tissue from pd patients [ 29,30 ] .
a recent proteomic analysis of mitochondria - enriched fractions from post - mortem pd substantia nigra revealed differential expression of multiple mitochondrial proteins in pd brains as compared with control brains [ 23 ] .
in further support for a " mitochondrial genetics " hypothesis for pd pathophysiology , bender et al .
[ 31 ] reported higher levels of mitochondrial dna deletions in nigral neurons from pd patients .
moreover , both bender et al .
[ 31 ] and kraytsberg et al .
[ 32 ] reported higher levels of mitochondrial dna deletions in nigral neurons of aged humans with sharp elevations starting shortly before age 70 .
this correlates with the known risk factor of age in pd. it is possible that there is an accumulation of mitochondrial dysfunction and of reactive oxygen species ( ros ) damage during aging which needs to reach a critical threshold for cellular dysfunction and degeneration to be observed .
how a systemic dysregulation in mitochondrial function or oxidative damage leads to tissue or cell type specific vulnerability still remains to be elucidated .
taken together , although studies over many years on pd indicate an important role of mitochondria in pd - associated pathology , the process by which the mitochondria become dysfunctional in pd and whether correction of mitochondrial defects could provide neuroprotection in pd remain to be determined .
3. environmental toxins that influence mitochondrial function some toxins used to model da loss in pd , such as mptp and rotenone , impair respiratory chain function by inhibiting complex i [ 33,34,35,36 ] .
these complex i inhibitors replicate some of the key motor features of pd and lead to da neuronal loss .
intravenous injection of the compound mptp by drug addicts caused a condition that closely resembles the anatomic and clinical features of pd [ 37,38 ] .
multiple models have been developed in the laboratory in which the chronic infusion of the pesticide rotenone or combination of herbicides and pesticides [ 39 ] lead to a pattern of cell death and da loss similar to that of pd. the precise role of environmental toxins in the cause of pd remains to be defined , but these data support the hypothesis that environmental toxins could introduce mitochondrial dysfunction and lead to parkinsonism in human .
indeed , epidemiological studies showed that the prevalence of sporadic pd is higher among farming communities [ 40 ] .
exposure to pesticides or herbicides elicited a three - to fourfold increased risk of developing pd [ 41 ] .
all of these data suggest an environmental contribution to the etiology of sporadic pd .
4. genetic factors associated with pd in a twin study , tanner et al. showed that for early onset cases , monozygotic concordance was twice that of dizygotic concordance , suggesting that genetic factors are important in the early onset pd [ 42 ] .
many examples of familial parkinsonism have also been reported ( see review [ 43 ]) .
mutations of several genes have been linked to familial pd and parkinsonian syndromes [ 44,45,46 ] .
4.1 .
mitochondrial dna mutations and deletions in pd mitochondrial dna ( mtdna ) encodes 13 subunits of respiratory chain proteins , including seven complex i , one complex iii , three complex iv , and two complex v subunits .
until now , there has been no pd - associated genetic mutations in mtdna reported [ 47 ] .
however , mtdna deletions have been observed in individual dopaminergic neurons dissected from postmortem human substantia nigra tissue [ 31 ] .
in addition , mutations in the gene encoding human mtdna polymerase subunit gamma ( polg ) leads to clinical parkinsonism associated with multiple mtdna deletions .
[ 48,49 ] .
furthermore , proliferator - activated coactivator - 1 alpha ( pgc - 1 alpha ) , one of the key regulators of mitochondrial biogenesis , was found to be decreased in pd patients through a genome - wide association study ( gwas ) [ 50 ] .
directed deletion of transcriptional factor a ( tfam ) in mouse da neurons using the cre - loxp system , termed as mitopark mice , causes marked deletion of mtdna , severe impairment of oxidative phosphorylation and slowly progressive motor deficits in the da system that mimic human parkinsonism as well as altered response to l - 3,4 - dihydroxyphenylalanine ( l - dopa ) treatment [ 51,52,53 ] .
the mitopark mice of pd provided direct evidence that mitochondrial dysfunction in da neurons can causes pd - related phenotypes .
consistently increased level of mtdna deletions in the striatum of pd patients have been reported [ 54 ] and mtdna deletions were significantly higher in neurons with impaired cytochrome oxidase activity [ 31,32 ] .
these findings support a mitochondrial genetic contribution in pd .
4.2 .
nuclear gene mutations affecting mitochondrial function many of the pd susceptible genes identified are related to mitochondrial function ( table 1 ) .
these genes and their potential contribution to pd have previously been extensively reviewed [ 43 ] .
pd linked genes that affect mitochondrial function include , but are not limited to , alpha - synuclein , parkin , phosphatase and tensin homologue ( pten ) - induced putative kinase 1 ( pink1 ) , dj - 1 and lrrk2 .
in this review we will focus on their involvement and effects on dysregulation of mitochondrial dynamics , mitophagy and mitochondrial redox , and mitochondrial protein import .
alpha - synuclein : alpha - synuclein is aggregation - prone protein which attains an increased propensity to aggregate because of the presence of its hydrophobic non - amyloid beta component domain .
missense mutations in the alpha - synuclein gene are associated with autosomal dominant pd [ 55 ] .
the fibrillar form of alpha - synucleinis a major component of lewy bodies and has been demonstrated to trigger neurotoxicity in pd [ 56,57 ] .
parkin : parkin is a ring finger containing ubiquitin e3 ligase .
it is known to mediate poly - ubiquitination of its substrates for proteasomal degradation .
mutations in the parkin gene cause early onset juvenile autosomal recessive pd , and parkin mutations are the most common cause of young onset pd. the loss of parkin e3 ligase activity results in accumulation of its substrates leading to neurotoxicity in autosomal recessive pd [ 58,59 ] .
pink1 : phosphatase and tensin homologue ( pten ) - induced putative kinase 1 ( pink1 ) is a serine / threonine kinase localized in mitochondria .
mutations in pink1 are associated with a rare form of autosomal recessive pd. pink mutations result in the loss of pink1 function which leads to aberrant phosphorylation of its substrates to cause pd [ 60,61 ] .
ijms - 16 - 20704 - t001 _ table 1 table 1 animal models of parkinson 's disease ( pd ) - related genes affect mitochondrial function .
animal models genetic manipulation in animals motor phenotypes pd pathology and mitochondrial function references alpha - synuclein transgenic mice ha53t alpha - synuclein in mice ; mprp promoter severe leading to paralysis and premature death lewy body - like inclusion in older mice ; mitochondrial dysfunction ; no dopaminergic neuronal loss [ 62,63,64 ] ha30p alpha - synuclein in mice ; mthy - 1 promoter severe leading to paralysis lewy body - like inclusion ; sensorimotor neuronal loss in brain stem [ 65 ] alpha - synuclein overexpression in mice ( thy1 promoter ) progressive declines in spontaneous and motor activity no da neuronal degeneration , mitochondrial dysregulation [ 66,67 ] ha53t alpha - synuclein expressing in sn da neurons of mice body weight loss ; normal locomotion activity progressive da neuronal loss ; aberrant mitochondrial inclusion [ 68 ] lrrk2 transgenic or knock - in mice lrrk2 r1441g mice ; bac promoter rearing activity decrease in older mice da neurite degeneration ; tau phosphorylation increase ; no da neuronal degeneration ; mitochondrial dysfunction [ 69,70 ] lrrk2 g2019s knock - in mice absent abnormal mitochondrial morphology ; mitochondrial dysfunction ; no da neuronal loss [ 71 ] parkin - / - mice parkin germline inactivation conflicting : either absent or subtle motor movement disturbance absent [ 72,73 ] dj1 - / - mice dj1 germline inactivation age - dependent declines in locomotor activity impaired da update ; no da neuronal degeneration [ 74 ] pink1 - / - mice pink1 germline inactivation age - dependent declines in spontaneous activity impaired da update ; no da neuronal degeneration ; mitochondrial abnormalities [ 75,76 ] mito - park mice dat riven cre ; loxed p tfam begins at 3 - 4 months ; declines in spontaneous and rearing activity abnormal mitochondrial aggregates ; da reduction in the striatum ; progressive da neuronal degeneration [ 51 ] double - mutant mice a53t alpha - synuclein overexpression in parkin - / - mice absent altered mitochondrial structure and morphology ; no da neuronal loss [ 77 ] dj - 1 : dj - 1 belongs to the peptidase c56 family of proteins .
wild - type dj - 1 can serve as a chaperone , protease , regulator of transcription and autophagy through redox regulation .
dj - 1 seems to be cytoprotective specifically under conditions related to oxidative stress .
its protective action is the result of the modification of cysteine residues on dj - 1 to cysteine - sulfinic and cysteine - sulfonic acids under oxidative stress [ 78 ] .
dj - 1 mutations associated with pd are rare and account for 1 % - 2 % of autosomal recessive early - onset pd [ 79 ] .
lrrk2 : leucine - rich repeat kinase 2 ( lrrk2 ) is a protein encoded by the park8 locus .
it has a conserved serine - threonine kinase mitogen - activated protein kinase kinase kinase ( mapkkk ) domain , a member of the roc ( ras of complex ) gtpase family [ 80,81,82 ] .
to date , there are over 50 variants identified in pd patients .
the mutation g2019s ( gly2019 to ser ) that takes place in the mapkkk domain has been recognized as the most common cause of dominant familial pd and accounts for up to 2 % of sporadic pd cases [ 83 ] .
the g2019s mutant augments the kinase activity of lrrk2 , which is associated with increased toxicity in dopaminergic neurons [ 84 ] .
4.3 .
mitochondrial dynamics impairment in parkinson 's disease mitochondria are organized in a highly dynamic tubular network that is continuously reshaped by opposing processes of fusion and fission [ 85 ] .
mitochondrial fission and fusion were first observed in yeast , and since have been observed in all mammalian cells [ 86 ] .
a delicate balance is maintained between fusion and fission to ensure the normal function of mitochondria .
specifically the fusion process is important for mitochondrial interactions and communication , and fission facilitates the segregation of mitochondria into daughter cells and enhances mitochondrial renewal and distribution along cytoskeletal tracks .
fusion and fission events enable the proper exchanging and mixing of mitochondrial membranes and contents .
this dynamic process controls not only mitochondrial morphology , but also the subcellular location and function of mitochondria .
defects in either fusion or fission limit mitochondrial motility , decrease energy production and increase oxidative stress , thereby promoting cell dysfunction and death [ 87,88 ] .
the two opposing processes , fusion and fission , are controlled by evolutionarily conserved large gtpases that belong to the dynamin family of proteins .
in mammalian cells , mitochondrial fusion is regulated by mitofusin - 1 and - 2 ( mfn1 / 2 ) and optic atrophy 1 ( opa1 ) , whereas mitochondrial fission is controlled by the dynamin - 1 - related protein , ( drp1 ) [ 89,90 ] and its mitochondrial adaptors such as fis1 , mff and mid49 / 51 [ 91,92,93 ] .
drp1 is primarily found in the cytosol , but it translocates from the cytosol to the mitochondrial surface in response to various cellular stimuli to regulate mitochondrial morphology [ 1 ] .
at the mitochondrial surface , drp1 is thought to wrap around the mitochondria to induce fission using its gtpase activity [ 94 ] .
in terms of pd , no mutations in typical mitochondria fission and fusion genes have yet been identified in pd patients .
however , increasing evidence from both toxin models and genetic mutations in pd animal models supports the hypothesis that mitochondrial dynamic regulation and dysfunction are involved in pd. evidence from toxin - induced pd models support a role for mitochondrial fission / fusion in the pathogenesis of pd. the parkinsonian neurotoxins , 6 - hydroxy dopamine ( 6 - ohda ) , rotenone , and mpp + , all induce mitochondrial fragmentation , leading to dopaminergic cell death in neuronal cultures [ 91,95,96 ] .
inhibition of pro - fission drp1 or overexpression of pro - fusion protein mitofusin - 1 ( mfn1 ) using genetic techniques prevents both neurotoxin - induced mitochondrial fission and neuronal cell death [ 97,98,99 ] .
loss of mfn2 or conditional knockout of neuronal mfn2 in mice has recently been reported to result in age - dependent motor deficits , followed by the loss of dopaminergic terminals in the striatum [ 100,101 ] , suggesting a role for mfn2 in parkinsonism .
also , drp1 is required for synaptic formation [ 102 ] and lack of drp1 leads to an impairment of brain development in mice [ 103,104 ] .
recently it has been reported that the drp1 is critical for targeting mitochondria to the terminal synapses of dopaminergic neurons and deletion of drp1 gene in dopaminergic neurons rapidly eliminates da terminals in the caudate - putamen and causes cell bodies in the midbrain to degenerate and lose alpha - synuclein [ 105 ] .
taken together , all these support that molecular machinery which maintains the balance of fusion and fission dynamics in the cells might contribute to the pathogenesis of pd. in addition , several genes , whose mutated forms are associated with familial pd , affect mitochondrial dynamics : these include pink1 , parkin , lrrk2 and dj - 1 [ 45,94,96,106,107,108,109,110 ] .
among these genes , the role of pink1 / parkin pathway in regulation of mitochondrial dynamics seems to be opposite from lrrk2 and dj - 1 ; mutations in pink1 / parkin lead to mitochondrial fusion [ 44,111 ] whereas mutations in lrrk2 or dj - 1 promote mitochondrial fission [ 44,112 ] .
fibroblasts from pd patients carrying pink1 or parkin mutations exhibited a more fragmented mitochondrial network , showing mitochondrial dysfunction [ 113,114 ] .
the mitochondrial network could also be reduced by the depletion of drp1 , or overexpression of opa1 or mfn2 [ 115,116,117,118 ] .
deficiency in dj - 1 in cell lines , cultured neurons and lymphoblasts derived from dj - 1 - deficient patients displayed aberrant mitochondrial morphology [ 119 ] .
further , in double - mutant mice in which alpha - synuclein mutant is overexpressed and parkin is ablated , severe genotype - , age - and region - dependent mitochondrial morphological alterations were found in neuronal somata .
the number of structurally altered mitochondria was significantly increased in the sn of these double - mutants mice [ 77 ] .
these studies further support the involvement of vulnerable genes in mitochondrial dynamics regulation in pd. wild - type lrrk2 interacts and colocalizes with several key regulators of mitochondrial fusion / fission , suggesting that it might have multiple regulatory roles [ 120 ] .
furthermore , mutant lrrk2 g2019s , the most common mutation in the population of familial pd patients , has been recently demonstrated to interact with drp1 and to promote mitochondrial fragmentation , leading to mitochondrial dysfunction and neuronal abnormalities [ 121,122 ] .
this fragmentation can be reduced by expression of the dominant - negative drp1k38a or overexpression of the fusion protein mfn2 [ 121,122 ] .
ips cells derived from pd patients carrying the g2019s mutation show excessive mitochondrial fission , aberrant autophagy and neuronal damage in da neurons differentiated in vitro [ 123 ] .
more importantly , treatment with p110 , a selective peptide inhibitor of drp1 recently developed in qi 's group [ 124,125 ] , reduced mitochondrial fragmentation and damage , and corrected excessive autophagy .
in this study it was also shown that g2019s mutated lrrk2 protein primarily phosphorylates drp1 at t595 resulting in aberrant mitochondrial fragmentation [ 123 ] .
together , these findings suggest that impairment of mitochondrial dynamics might contribute to the pathogenesis and progression of pd .
5. mitophagy / autophagy impairment in parkinson 's disease autophagy is a process of cellular degradation in which cargos are degraded by autophagosomes fused with lysosomes [ 126 ] .
in addition to non - selective cargos , autophagosomes can degrade protein aggregates or damaged mitochondria .
mitochondria - associated autophagy ( mitophagy ) is regulated by autophagy receptors that preferentially bind ubiquitylated mitochondria and subsequently recruit the autophagosome protein light chain 3 ( lc3 ) through their lc3 - interaction region ( lir ) motif [ 127 ] .
lc3 in mammals , also known as atg8 in yeast , plays crucial roles in both autophagosome membrane biogenesis and cargo recognition [ 128,129 ] .
in yeast , atg32 functions as a receptor on mitochondria to initiate mitophagy through its interaction with atg8 [ 130,131 ] .
in mammals , fundc1 [ 132 ] , p62 [ 133 ] , bnip3 [ 134 ] , and ambra1 [ 135 ] , have been recognized as receptors for mitophagy , all of which bind to lc3 via the lir motif [ 136 ] .
the implication of these receptors in mitophagy regulation , however , seems to be dependent of experimental conditions. whether and how these receptors cooperatively regulate mitophagy remains to be determined .
a number of lines of evidence suggest a critical role for defective autophagy / mitophagy in neurodegeneration in pd. cultured cells exposed to parkinsonian neurotoxins such as mpp + , rotenone , or 6 - ohda showed an increased number of autophagosomes and associated neuronal cell death [ 125,137,138 ] .
in recent years , pink1 - depenent activation of parkin has been recognized as a major pathway of mitophagy [ 139 ] .
in mammalian cells , parkin is recruited to depolarized mitochondria , which are subsequently eliminated by autophagy .
such parkin recruitment to mitochondria depends on pink1 accumulation on mitochondria and therefore pink1 is a key molecule in the signal transduction of mitophagy [ 140 ] .
the failure of pink1 / parkin - mediated mitophagic process leads to accumulation of damaged mitochondria , which results in an increase in ros and cell death [ 141,142 ] .
because these studies were all conducted in cells with overexpression of pink1 and parkin and because parkin at endogenous levels fail to mediate mitophagy in pd patient cells [ 143 ] , the matter of whether these proteins , at the endogenous levels , cooperatively regulate mitophagy remains to be validated .
knock - down of dj - 1 , another pd - related gene , resulted in decreased mitochondrial membrane potential , increased reactive oxygen species , excessive mitochondrial fragmentation and impaired autophagy [ 74,119,144 ] .
interestingly , overexpression of pink1 and parkin can rescue mitochondrial fragmentation and dysfunction induced by the depletion of dj - 1 [ 145,146 ] .
given that wild - type and mutant dj - 1 can interact with pink1 [ 147 ] and that parkin , as an e3 ligase on mitochondria , catalyzes the ubiquitination of dj - 1 [ 148 ] , pink1 , parkin and dj - 1 may be operative in the pathway of pink1 / parkin - mediated mitophagy .
pathogenic lrrk2 - mediated autophagy has been observed in a variety of cell cultures [ 149,150 ] , in neurons derived from patient - induced pluripotent stem cells [ 151 ] and in animal models in which a mutant form of lrrk2 is expressed [ 152 ] .
either knock - down of lrrk2 by sirna or treatment with a lrrk2 kinase inhibitor caused an increase in autophagic fluxin - cultured cells [ 153,154 ] .
overexpression of lrrk2 , especially mutant forms , seems to suppress autophagy [ 155 ] .
in contrast , studies from other two groups show that mutant forms of lrrk2 may induce autophagy via an erk1 / 2 - dependent pathway [ 149,156 ] .
although the detailed mechanisms by which lrrk2 and its mutants mediate autophagy are not clear , lrrk2 may disrupt the balance of autophagy through damaging lysosome - related calcium storage and cargo degradation [ 157,158 ] .
further , our group recently reported excessive mitophagy in a variety of cells expressing the lrrk2 g2019s mutant , which was accompanied by mitochondrial depolarization , recruitment of p62 to the mitochondria , increased lc3ii levels and lysosomal activity as well as death of dopaminergic neurons [ 123,159 ] .
we showed that the lrrk2 g2019s mutant caused excessive mitophagyby phosphorylating its substrate including fission protein drp1 and mitochondrial outer membrane protein bcl2 [ 123,159 ] .
thus , the pathway that lrrk2 mediation of mitophagy might be different from those occurred during autophagy .
taken together , a large body of studies indicates that the different pd - related genes contribute to the pathogenesis of pd at the intersection of mitochondrial dysfunction and autophagy .
the loss of mitochondrial membrane potential , which is associated with mitochondrial dysfunction , seems to be a common signal for mitochondria to be degraded via mitophagy .
moreover , occurrence of mitochondrial fragmentation due to impairment of mitochondrial fusion and fission often precedes the induction of mitophagy .
thus , it is possible that mitophagy may be a multistep process starting with the degradation of profusion / fission proteins , resulting in an imbalance of mitochondrial dynamics and the subsequent clearance of mitochondria [ 86 ] .
however , the factors that regulate these processes involved in mitochondrial " quality control " , including mitochondrial dynamics , mitochondria - associated degradation and mitophagy in pd , remain to be determined .
6. mitochondrial redox signaling in parkinson 's disease decreased complex i activity in the sn of pd patients and animal models has been repeatedly observed .
the defect in complex i results in impairment of electron transport and causes ros accumulation in mitochondria which lead to neuronal degeneration .
neurotoxins causing parkinsonism , mpp + are selectively taken up into dopaminergic neurons in which it inhibits complex i activity [ 160 ] .
rotenone also inhibits complex i by impairing oxidative phosphorylation [ 161 ] .
these studies demonstrate a contribution from ros to the pathogenesis of dopamine neuronal loss in pd. the genetic pd - linked proteins play a significant role in this process .
alpha - synuclein mutant a53t can enter mitochondria where it binds to the complex i subunit to inhibit complex i activity , producing ros [ 162,163 ] .
functional studies showed that alpha - synuclein associated with mitochondria induces cytochrome c release , increased calcium and ros levels resulting in dopaminergic neuronal death [ 164 ] .
in addition , expression of mutants of pd - related genes parkin , pink1 , dj - 1 and lrrk2 in cultured cells all increased ros .
this evidence has been well - summarized in other reviews [ 29,165 ] .
however , it is uncertain if such elevated ros are directly caused by these mutants or through indirect cellular effects .
besides ros , reactive nitrogen species ( rns ) mediating nitrosative stress is also implicated in sn neuronal loss in pd [ 166 ] .
rns are generated by the reaction of superoxide with nitric oxide ( no ) , which results in the production of peroxynitrite .
no inhibits several enzymes including complexes i and iv of the mitochondrial electron transport chain , which in turn lead to ros generation [ 167,168 ] .
increased expression of inos and nnos were observed in basal ganglia of postmortem brain of pd patients [ 169 ] .
in the mouse mptp model , there was a significant upregulation of inos associated with the gliosis in the sn [ 170 ] .
inhibition of nnos has been reported to protect against neurotoxicity in mptp - induced pd animal model [ 171,172 ] .
these observations suggest that no and its metabolite peroxynitriteare implicated in the pathogenesis of pd .
7. mitochondrial protein import in parkinson 's disease mitochondria possess their own dna and translational machinery ; however , there are only a small number of mitochondrial proteins encoded by mtdna that are synthesized within the organelle .
the majority of mitochondrial proteins are nuclear - encoded and have to be imported into the organelle .
the translocase of the outer mitochondrial membrane ( tom complex ) plays central roles in controlling protein entry to mitochondria [ 173 ] .
the tom complex is the main entry portal for most mitochondrial proteins that are synthesized in cytoplasm .
the tom complex contains seven subunits including tom40 , tom22 , two proprotein receptors , tom20 , and tom70 , and three smaller proteins , tom5 , tom6 and tom7 .
in general , imported proteins bind to one of these receptors. with the assistance of tom22 and tom5 , the imported proteins pass the tom 40 channel [ 174 ] .
tom complexes also need to cooperate with tim ( translocase of the inner membrane ) 23 complexes to import matrix - targeted proteins [ 175 ] .
thus , the tom and the tim23 complex direct the translocation of oxidative phosphorylation and metabolite transporter proteins to the inner membrane .
a number of studies have reported that pd - associated genes , alpha - synuclein , pink1 and parkin can interact with the tom complex , disrupting the mitochondrial protein import .
alpha - synuclein can enter mitochondria where it mainly localizes at the inner membrane .
the import of alpha - synuclein to mitochondria is through the tom complex [ 176,177 ] .
in postmortem brain samples of pd and in brain tissues of mice overexpressing alpha - synuclein , tom 40 levels changed together with the levels of alpha - synuclein [ 177 ] .
expression with either wild - type alpha - synuclein or mutant a53t in cultured cells resulted in the loss of tom40 , whereas over - expression of tom40 prevented the cellular damage caused by expression of either alpha - synuclein wild - type or its mutant a53t [ 177 ] .
thus , alpha - synuclein mutants may impair mitochondrial function by suppression of tom40 - dependent mitochondrial protein import pathways .
pink1 is also imported into the mitochondria via the tom complex channel [ 178,179 ] and then is degraded in a membrane potential - dependent manner .
under mitochondrial depolarization pink1 , interacting with the tom complex , recruits and activates parkin , leading to degradation of mitochondrial outer membrane proteins and ultimately mitophagy [ 178 ] .
thus , pathogenic mutations in pink1 and parkin may disrupt this pathway , resulting in the accumulation of dysfunctional mitochondria .
8. potential therapeutics targeting mitochondria for treatment of pd given the importance of mitochondrial dysfunction in the pathogenesis of pd , therapeutics targeting mitochondria have been studied to prevent or treat pd. although the cellular and pathological phenotypes from neurotoxin - induced and genetic mutant - associated pd models are different , the outcomes of mitochondrial dysfunction , including mitochondrial dynamic impairments , increased ros , and impaired bioenergetics , seem to be common pathways .
thus , the mechanistic information on mitochondrial dysfunction in pd models provides potential targets for the development of therapeutic approaches for treatment of pd. here , we summarize reported therapeutic agents that reduce pd pathology in models of pd ( see table 2 ) .
we categorize these agents into ( 1 ) modulating pd - related genetic mutants ; ( 2 ) modulating mitochondrial proteins ; and ( 3 ) modulating the consequences of mitochondrial dysfunction .
in table 2 , we list the neuroprotective effects of these agents especially in either animal models of pd or neuron derived patient - ips cells .
modulating pd - related genetic mutants : lrrk2 mutants are the most common genetic mutants in both familial and sporadic pd. modulation of the lrrk2 kinase domain has been attractive for the development of therapeutics of pd .
lrrk2 inhibitors , pf - 06447475 and gw5074 , have been shown to increase dopaminergic neuronal survival in primary neuronal cultures and neurons - derived from patient ips cells [ 180,181 ] .
increasing glyoxalase activity of dj - 1 by supplying d - lactate and glycolate rescues the requirement for dj - 1 in maintenance of mitochondrial potential , increases cytocatalytic rate of dj - 1 , and reduces neuronal death caused by paraquat and down - regulation of pink1 [ 182 ] .
however , thus far , these reagents are only tested in cultured cells so far. whether treatment with these pharmacological agents protect neurons from pd in animal models remains to be determined .
ijms - 16 - 20704 - t002 _ table 2 table 2 therapeutic agents that target mitochondria for treatment of parkinson 's disease category agent molecular action pd mode therapeutic effects modulating pd - related genes pf - 06447475 lrrk2 kinase inhibitor transgenic rat with lrrk2 g2019s reduce behavioral and neuropathological phenotypes reduce inflammation [ 183 ] gw5074 lrrk2 kinase inhibitor da neurons derived from pd patient ips cells suppression of ros improve mitochondrial respiration increase da neuronal survival [ 180 ] fx2149 lrrk2 gtpase inhibitor mouse inflammation model reduce neuroinflammation inhibit microglial activity [ 184 ] modulating mitochondrial protein alda - 1 aldh2 activator rotenone - and mptp - induced animal models improve mitochondrial membrane potential inhibit mitochondrial ros reduce dopaminergic cell death [ 185 ] tro40303 inhibitor of mitochondrial transition pore mice expressing alha - synuclein upregulate mitochondrial proteins increase th expression [ 186 ] p110 peptide inhibitor of drp1 da neurons from lrrk2 g2019s pd patient ips cells improve mitochondrial membrane potential inhibit mitochondrial ros increase mitochondrial integrity reduce autophagy improve da neuronal morphology and survival [ 123 ] mdivi - 1 inhibitor of mitochondrial fragmentation mptp - induced mouse pd model improve mitochondrial morphology improve mouse behavioral outcome pink1 - / - mouse model reduce da neuronal loss in sn restore dopamine level [ 187 ] modulating mitochondrial dysfunction q1 8 - oh - quinoline - based iron chelator mptp - induced mouse pd model reduce da neuronal degeneration in sn decrease mitochondrial iron pool [ 188 ] rapamycin mtor inhibitor 6 - ohda - induced rat pd model inhibit oxidative stress inhibit mitochondrial apoptosis [ 189 ] edaravone ros scavenger rotenone - induced rat pd model inhibit mitochondrial apoptosis reduce ros [ 190 ] melatonin antioxidant rotenone - induced rat pd model suppress calcium level 6 - ohda - induced rat pd model inhibit mitochondrial ros enhance complex i activity [ 191,192 ] quercetin bioflavonoid rotenone - induced rat pd model inhibit mitochondrial ros generation inhibit p53 level inhibit nuclear translocation of nf - kappab inhibit mitochondrial apoptosis [ 193 ] cnb - 001 curcumin derivative mptp - induced mouse pd model improve mitochondrial morphology inhibit mitochondrial apoptotic pathway improve mitochondrial membrane potential [ 194 ] alpha - lipoic acid antioxidant rotenone - induced rat pd model increase mitochondrial complex i activity inhibit ros generation increase mitochondrial biogenesis increase glutathione [ 195 ] lycopene chemical carotene rotenone - induced rat pd model inhibit mitochondrial apoptotic pathway increase sod activity increase glutathione inhibit lipid peroxidation [ 196 ] modulating mitochondrial proteins : aldehyde dehydrogenase 2 ( aldh2 ) , located in mitochondrial matrix , functions as a cellular protector against oxidative stress by detoxification of cytotoxic aldehydes .
alda - 1 is a small molecule that enhances aldh enzyme activity and protects against oxidative toxicity [ 197 ] .
treatment with alda - 1 can reduce rotenone - induced apoptosis in both sh - sy5y cells and primary dopaminergic neurons .
moreover , intraperitoneal administration of alda - 1 can improve mitochondrial membrane potential , inhibit mitochondrial ros and reduce death of tyrosine hydroxylase ( th ) - positive dopaminergic neurons in rotenone - or mptp - induced pd animal models [ 185 ] .
cholesterol oximes such as olesoxime and tro40303 are small molecules that interact with the mitochondrial outer membrane protein vdac and limit opening of the mitochondrial transition pore in response to oxidative stress [ 198 ] .
olesoxime can protect differentiated shsy - 5y cells from cell death , and reduce neurite retraction and cytoplasmic shrinkage induced by alpha - synuclein overexpression [ 199 ] .
low dose tro40303 upregulates a number of mitochondrial proteins including drp1 and vdac and enhances expression of tyrosine hydroxylase in mice overexpressing alpha - synuclein [ 186 ] .
as mentioned above , our group has developed a peptide inhibitor p110 that selectively blocks the protein - protein interactions between drp1 and its mitochondrial adaptor fis1 [ 125 ] .
treatment with p110 significantly reduced mitochondrial fragmentation , decreased mitochondrial ros and improved mitochondrial integrity in dopaminergic neurons exposed to mpp + in neurons expressing the lrrk2 g2019s mutation , and in dopaminergic neurons derived from lrrk2 g2019s patient - ips cells [ 123,125 ] .
importantly , we showed that treatment with p110 had minor effects on mitochondrial dynamics and neuronal survival under physiological conditions [ 123,125 ] .
in addition , mdivi - 1 , an inhibitor of mitochondrial fragmentation , was reported to reduce behavioral and neuropathological phenotypes in an mptp - induced pd mouse model , in addition to its protective effects in dopaminergic neurons exposed to neurotoxins [ 187 ] .
modulating the consequences of mitochondrial dysfunction : modulation of downstream mitochondrial dysfunction may also provide therapeutic opportunities , in both sporadic and familial pd. in the past decades , a number of natural products and small molecules have been reported to protect against neuropathology associated with pd , at least in part through protecting mitochondria .
treatment with these agents has been shown to reduce mitochondrial ros , inhibit mitochondrial apoptotic pathways , and increase mitochondrial complex i activity .
as a consequence , treatment with these agents can reduce neuronal degeneration in pd in culture and in animals .
these agents have been extensively reviewed [ 200,201,202,203 ] .
here , we only list those that have significant protection in animal models of pd ( table 2 ) .
9. concluding remarks accumulating evidence supports the hypothesis that mitochondrial abnormalities and dysfunction could critically influence neuronal degeneration in both sporadic and faimilial pd. dysregulation of mitochondrial dynamics and mitophagy have been centrally implicated in the neuropathology of pd. this evidence supports the idea that mitochondrial damage might be a primary cause initiating the progression of pd. thus , targeting mitochondria may offer the opportunities for drug development to treat neurodegenerative diseases such as parkinsonism .
conflicts of interest the authors declare no conflict of interest .
references 1 .
duvoisin r.c. overview of parkinson 's disease ann. n. y. acad. sci. 1992 648 187 193 10.1111 / j.1749 - 6632.1992.tb24537.x 1637046 2 .
dauer w. przedborski s. parkinson 's disease : mechanisms and models neuron 2003 39 889 909 10.1016 / s0896 - 6273 ( 03 ) 00568 - 3 12971891 3 .
dawson t.m. dawson v.l. molecular pathways of neurodegeneration in parkinson 's disease science 2003 302 819 822 10.1126 / science.1087753 14593166 4 .
yao z. wood n.w. cell death pathways in parkinson 's disease : role of mitochondria antioxid .
redox signal .
2009 11 2135 2149 10.1089 / ars.2009.2624 19422283 5 .
ellis c.e. murphy e.j. mitchell d.c. golovko m.y. scaglia f. barcelo - coblijn g.c. nussbaum r.l. mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha - synuclein mol. cell. biol .
2005 25 10190 10201 10.1128 / mcb.25.22.10190 - 10201.2005 16260631 6 .
herrmann j.m. longen s. weckbecker d. depuydt m. biogenesis of mitochondrial proteins adv. exp. med. biol .
2012 748 41 64 22729854 7 .
sas k. robotka h. toldi j. vecsei l. mitochondria , metabolic disturbances , oxidative stress and the kynurenine system , with focus on neurodegenerative disorders j. neurol. sci. 2007 257 221 239 10.1016 / j.jns.2007.01.033 17462670 8 .
daiber a. redox signaling ( cross - talk ) from and to mitochondria involves mitochondrial pores and reactive oxygen species biochim. biophys .
acta 2010 1797 897 906 10.1016 / j.bbabio.2010.01.032 20122895 9 .
bononi a. missiroli s. poletti f. suski j.m. agnoletto c. bonora m. de marchi e. giorgi c. marchi s. patergnani s. mitochondria - associated membranes ( mams ) as hotspot ca2 + signaling units adv. exp. med. biol .
2012 740 411 437 22453952 10 .
rizzuto r. de stefani d. raffaello a. mammucari c. mitochondria as sensors and regulators of calcium signalling nat. rev. mol .
cell biol .
2012 13 566 578 10.1038 / nrm3412 22850819 11 .
cali t. ottolini d. brini m. mitochondrial ca2 + as a key regulator of mitochondrial activities adv. exp. med. biol .
2012 942 53 73 22399418 12 .
osteryoung k.w. nunnari j. the division of endosymbiotic organelles science 2003 302 1698 704 10.1126 / science.1082192 14657485 13 .
antico arciuch v.g. elguero m.e. poderoso j.j. carreras m.c. mitochondrial regulation of cell cycle and proliferation antioxid .
redox signal .
2012 16 1150 1180 10.1089 / ars.2011.4085 21967640 14 .
moyes c.d. hood d.a. origins and consequences of mitochondrial variation in vertebrate muscle annu. rev. physiol .
2003 65 177 201 10.1146 / annurev.physiol.65.092101.142705 12524465 15 .
schatten h. prather r.s. sun q.y. the significance of mitochondria for embryo development in cloned farm animals mitochondrion 2005 5 303 321 10.1016 / j.mito.2005.05.003 16150655 16 .
giorgi c. baldassari f. bononi a. bonora m. de marchi e. marchi s. missiroli s. patergnani s. rimessi a. suski j.m. mitochondrial ca2 + and apoptosis cell calcium 2012 52 36 43 10.1016 / j.ceca.2012.02.008 22480931 17 .
rasola a. bernardi p. mitochondrial permeability transition in ca2 + - dependent apoptosis and necrosis cell calcium 2011 50 222 233 10.1016 / j.ceca.2011.04.007 21601280 18 .
wang c. youle r.j. the role of mitochondria in apoptosis * annu. rev. genet .
2009 43 95 118 10.1146 / annurev - genet - 102108 - 134850 19659442 19 .
burbach j.p. smits s. smidt m.p. transcription factors in the development of midbrain dopamine neurons ann. n. y. acad. sci. 2003 991 61 68 10.1111 / j.1749 - 6632.2003.tb07463.x 12846974 20 .
wallen a. perlmann t. transcriptional control of dopamine neuron development ann. n. y. acad. sci. 2003 991 48 60 10.1111 / j.1749 - 6632.2003.tb07462.x 12846973 21 .
dreyer s.d. zhou g. baldini a. winterpacht a. zabel b. cole w. johnson r.l. lee b. mutations in lmx1b cause abnormal skeletal patterning and renal dysplasia in nail patella syndrome nat. genet .
1998 19 47 50 10.1038 / ng0598 - 47 9590287 22 .
smidt m.p. van schaick h.s. lanctot c. tremblay j.j. cox j.j. van der kleij a.a. wolterink g. drouin j. burbach j.p. a homeodomain gene ptx3 has highly restricted brain expression in mesencephalic dopaminergic neurons proc .
natl acad. sci. usa 1997 94 13305 13310 10.1073 / pnas.94.24.13305 9371841 23 .
smidt m.p. asbreuk c.h. cox j.j. chen h. johnson r.l. burbach j.p. a second independent pathway for development of mesencephalic dopaminergic neurons requires lmx1b nat. neurosci .
2000 3 337 341 10725922 24 .
mann v.m. cooper j.m. daniel s.e. srai k. jenner p. marsden c.d. schapira a.h. complex i , iron , and ferritin in parkinson 's disease substantia nigra ann. neurol .
1994 36 876 881 10.1002 / ana.410360612 7998774 25 .
blandini f. nappi g. greenamyre j.t. quantitative study of mitochondrial complex i in platelets of parkinsonian patients mov. disord .
1998 13 11 15 10.1002 / mds.870130106 9452319 26 .
haas r.h. nasirian f. nakano k. ward d. pay m. hill r. shults c.w. low platelet mitochondrial complex i and complex ii / iii activity in early untreated parkinson 's disease ann. neurol .
1995 37 714 722 10.1002 / ana.410370604 7778844 27 .
barroso n. campos y. huertas r. esteban j. molina j.a. alonso a. gutierrez - rivas e. arenas j. respiratory chain enzyme activities in lymphocytes from untreated patients with parkinson disease clin. chem .
1993 39 667 69 8386068 28 .
yoshino h. nakagawa - hattori y. kondo t. mizuno y. mitochondrial complex i and ii activities of lymphocytes and platelets in parkinson 's disease j. neural transm parkinsons dis. dement. sect .
1992 4 27 34 10.1007 / bf02257619 29 .
dias v. junn e. mouradian m.m. the role of oxidative stress in parkinson 's disease j. parkinsons dis .
2013 3 461 491 24252804 30 .
hwang o. role of oxidative stress in parkinson 's disease exp. neurobiol .
2013 22 11 17 10.5607 / en.2013.22.1.11 23585717 31 .
bender a. krishnan k.j. morris c.m. taylor g.a. reeve a.k. perry r.h. jaros e. hersheson j.s. betts j. klopstock t. high levels of mitochondrial dna deletions in substantia nigra neurons in aging and parkinson disease nat. genet .
2006 38 515 517 10.1038 / ng1769 16604074 32 .
kraytsberg y. kudryavtseva e. mckee a.c. geula c. kowall n.w. khrapko k. mitochondrial dna deletions are abundant and cause functional impairment in aged human substantia nigra neurons nat. genet .
2006 38 518 520 10.1038 / ng1778 16604072 33 .
langston j.w. ballard p. tetrud j.w. irwin i. chronic parkinsonism in humans due to a product of meperidine - analog synthesis science 1983 219 979 980 10.1126 / science.6823561 6823561 34 .
betarbet r. sherer t.b. mackenzie g. garcia - osuna m. panov a.v. greenamyre j.t. chronic systemic pesticide exposure reproduces features of parkinson 's disease nat. neurosci .
2000 3 1301 1306 11100151 35 .
testa c.m. sherer t.b. greenamyre j.t. rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures brain res. mol .
brain res .
2005 134 109 118 10.1016 / j.molbrainres.2004.11.007 15790535 36 .
smeyne r.j. jackson - lewis v. the mptp model of parkinson 's disease brain res. mol .
brain res .
2005 134 57 66 10.1016 / j.molbrainres.2004.09.017 15790530 37 .
langston j.w. ballard p.a. jr. parkinson 's disease in a chemist working with 1 - methyl - 4 - phenyl - 1,2,5,6 - tetrahydropyridine n. engl. j. med. 1983 309 310 6602944 38 .
kopin i.j. toxins and parkinson 's disease : mptp parkinsonism in humans and animals adv. neurol .
1987 45 137 144 3493621 39 .
barbeau a. parkinson 's disease : clinical features and etiopahthology amsterdam handbook of clinical neurology viken p.j. bruyn g.w. klawans h.l. elsevier science publishers amsterdam , the netherlands 1986 87 108 40 .
jenner p. olanow c.w. understanding cell death in parkinson 's disease ann. neurol .
1998 44 suppl .
1 s72 s84 10.1002 / ana.410440712 9749577 41 .
nunes i. tovmasian l.t. silva r.m. burke r.e. goff s.p .
pitx3 is required for development of substantia nigra dopaminergic neurons proc. natl. acad. sci. usa 2003 100 4245 4250 10.1073 / pnas.0230529100 12655058 42 .
van den munckhof p. luk k.c. ste - marie l. montgomery j. blanchet p.j. sadikot a.f. drouin j .
pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons development 2003 130 2535 2542 10.1242 / dev.00464 12702666 43 .
klein c. westenberger a. genetics of parkinson 's disease cold spring harb. perspect. med. 2012 2 a008888 10.1101 / cshperspect.a008888 22315721 44 .
zetterstrom r.h. solomin l. jansson l. hoffer b.j. olson l. perlmann t. dopamine neuron agenesis in nurr1 - deficient mice science 1997 276 248 250 10.1126 / science.276.5310.248 9092472 45 .
wallen a. zetterstrom r.h. solomin l. arvidsson m. olson l. perlmann t. fate of mesencephalic ahd2 - expressing dopamine progenitor cells in nurr1 mutant mice exp .
cell res .
1999 253 737 46 10.1006 / excr.1999.4691 10585298 46 .
smidt m.p. smits s.m. burbach j.p. molecular mechanisms underlying midbrain dopamine neuron development and function eur. j. pharmacol .
2003 480 75 88 10.1016 / j.ejphar.2003.08.094 14623352 47 .
franco - iborra s. vila m. perier c. the parkinson disease mitochondrial hypothesis : where are we at ?
neuroscientist 2015 10.1177 / 1073858415574600 25761946 48 .
luoma p. melberg a. rinne j.o. kaukonen j.a. nupponen n.n. chalmers r.m. oldfors a. rautakorpi i. peltonen l. majamaa k. parkinsonism , premature menopause , and mitochondrial dna polymerase gamma mutations : clinical and molecular genetic study lancet 2004 364 875 882 10.1016 / s0140 - 6736 ( 04 ) 16983 - 3 15351195 49 .
henchcliffe c. beal m.f. mitochondrial biology and oxidative stress in parkinson disease pathogenesis nat. clin. pract. neurol .
2008 4 600 609 10.1038 / ncpneuro0924 18978800 50 .
zheng b. liao z. locascio j.j. lesniak k.a. roderick s.s. watt m.l. eklund a.c. zhang - james y. kim p.d. hauser m.a. pgc - 1alpha , a potential therapeutic target for early intervention in parkinson 's disease sci. transl med. 2010 2 52ra73 20926834 51 .
ekstrand m.i. terzioglu m. galter d. zhu s. hofstetter c. lindqvist e. thams s. bergstrand a. hansson f.s. trifunovic a. progressive parkinsonism in mice with respiratory - chain - deficient dopamine neurons proc. natl. acad. sci. usa 2007 104 1325 1330 10.1073 / pnas.0605208103 17227870 52 .
ekstrand m.i. galter d. the mitopark mouse - - an animal model of parkinson 's disease with impaired respiratory chain function in dopamine neurons parkinsonism relat. disord .
2009 15 suppl .
3 s185 s188 10.1016 / s1353 - 8020 ( 09 ) 70811 - 9 20082987 53 .
gellhaar s. marcellino d. abrams m.b. galter d. chronic l - dopa induces hyperactivity , normalization of gait and dyskinetic behavior in mitopark mice genes brain behav .
2015 14 260 270 10.1111 / gbb.12210 25752644 54 .
ikebe s. tanaka m. ohno k. sato w. hattori k. kondo t. mizuno y. ozawa t. increase of deleted mitochondrial dna in the striatum in parkinson 's disease and senescence biochem. biophys. res. commun .
1990 170 1044 1048 10.1016 / 0006 - 291x ( 90 ) 90497 - b 2390073 55 .
lee v.m. trojanowski j.q. mechanisms of parkinson 's disease linked to pathological alpha - synuclein : new targets for drug discovery neuron 2006 52 33 38 10.1016 / j.neuron.2006.09.026 17015225 56 .
peelaerts w. bousset l. van der perren a. moskalyuk a. pulizzi r. giugliano m. van den haute c. melki r. baekelandt v. synuclein strains cause distinct synucleinopathies after local and systemic administration nature 2015 522 340 344 10.1038 / nature14547 26061766 57 .
selkoe d. dettmer u. luth e. kim n. newman a. bartels t. defining the native state of alpha - synuclein neurodegener. dis .
2014 13 114 117 10.1159 / 000355516 24192542 58 .
riess o. jakes r. kruger r. genetic dissection of familial parkinson 's disease mol. med. today 1998 4 438 444 10.1016 / s1357 - 4310 ( 98 ) 01343 - 4 9793932 59 .
de silva h.r. khan n.l. wood n.w. the genetics of parkinson 's disease curr. opin. genet. dev .
2000 10 292 298 10.1016 / s0959 - 437x ( 00 ) 00082 - 4 10826990 60 .
tan j.m. dawson t.m. parkin blushed by pink1 neuron 2006 50 527 529 10.1016 / j.neuron.2006.05.003 16701203 61 .
kubo s. hattori n. mizuno y. recessive parkinson 's disease mov. disord .
2006 21 885 893 10.1002 / mds.20841 16615060 62 .
giasson b.i. duda j.e. quinn s.m. zhang b. trojanowski j.q. lee v.m. neuronal alpha - synucleinopathy with severe movement disorder in mice expressing a53t human alpha - synuclein neuron 2002 34 521 533 10.1016 / s0896 - 6273 ( 02 ) 00682 - 7 12062037 63 .
lee m.k. stirling w. xu y. xu x. qui d. mandir a.s. dawson t.m. copeland n.g. jenkins n.a. price d.l. human alpha - synuclein - harboring familial parkinson 's disease - linked ala - 53 - - > thr mutation causes neurodegenerative disease with alpha - synuclein aggregation in transgenic mice proc. natl. acad. sci. usa 2002 99 8968 8973 10.1073 / pnas.132197599 12084935 64 .
gispert s. del turco d. garrett l. chen a. bernard d.j. hamm - clement j. korf h.w. deller t. braak h. auburger g. transgenic mice expressing mutant a53t human alpha - synuclein show neuronal dysfunction in the absence of aggregate formation mol. cell. neurosci .
2003 24 419 429 10.1016 / s1044 - 7431 ( 03 ) 00198 - 2 14572463 65 .
neumann m. kahle p.j. giasson b.i. ozmen l. borroni e. spooren w. muller v. odoy s. fujiwara h. hasegawa m. misfolded proteinase k - resistant hyperphosphorylated alpha - synuclein in aged transgenic mice with locomotor deterioration and in human alpha - synucleinopathies j. clin. investig .
2002 110 1429 11439 10.1172 / jci200215777 12438441 66 .
rockenstein e. mallory m. hashimoto m. song d. shults c.w. lang i. masliah e. differential neuropathological alterations in transgenic mice expressing alpha - synuclein from the platelet - derived growth factor and thy - 1 promoters j. neurosci. res .
2002 68 568 578 10.1002 / jnr.10231 12111846 67 .
fleming s.m. salcedo j. fernagut p.o. rockenstein e. masliah e. levine m.s. chesselet m.f. early and progressive sensorimotor anomalies in mice overexpressing wild - type human alpha - synuclein j. neurosci .
2004 24 9434 9440 10.1523 / jneurosci.3080 - 04.2004 15496679 68 .
chen l. xie z. turkson s. zhuang x .
a53t human alpha - synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration j. neurosci .
2015 35 890 905 10.1523 / jneurosci.0089 - 14.2015 25609609 69 .
li y. liu w. oo t.f. wang l. tang y. jackson - lewis v. zhou c. geghman k. bogdanov m. przedborski s. mutant lrrk2 ( r1441g ) bac transgenic mice recapitulate cardinal features of parkinson 's disease nat. neurosci .
2009 12 826 828 10.1038 / nn.2349 19503083 70 .
dranka b.p. gifford a. mcallister d. zielonka j. joseph j. o'hara c.l. stucky c.l. kanthasamy a.g. kalyanaraman b. a novel mitochondrially - targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine - rich repeat kinase 2 ( lrrk2 ( r1441g )) transgenic mouse model of parkinson 's disease neurosci. lett .
2014 583 159 164 10.1016 / j.neulet.2014.09.042 25263790 71 .
yue m. hinkle k.m. davies p. trushina e. fiesel f.c. christenson t.a. schroeder a.s. zhang l. bowles e. behrouz b. progressive dopaminergic alterations and mitochondrial abnormalities in lrrk2 g2019s knock - in mice neurobiol. dis .
2015 78 172 195 10.1016 / j.nbd.2015.02.031 25836420 72 .
goldberg m.s. fleming s.m. palacino j.j. cepeda c. lam h.a. bhatnagar a. meloni e.g. wu n. ackerson l.c. klapstein g.j. parkin - deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons j. biol. chem .
2003 278 43628 43635 10.1074 / jbc.m308947200 12930822 73 .
perez f.a. palmiter r.d. parkin - deficient mice are not a robust model of parkinsonism proc. natl. acad. sci. usa 2005 102 2174 2179 10.1073 / pnas.0409598102 15684050 74 .
lopert p. patel m. brain mitochondria from dj - 1 knockout mice show increased respiration - dependent hydrogen peroxide consumption redox biol .
2014 2 667 672 10.1016 / j.redox.2014.04.010 24936441 75 .
akundi r.s. huang z. eason j. pandya j.d. zhi l. cass w.a. sullivan p.g. bueler h. increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in pink1 - deficient mice plos one 2011 6 e16038 10.1371 / journal.pone.0016038 21249202 76 .
gispert s. ricciardi f. kurz a. azizov m. hoepken h.h. becker d. voos w. leuner k. muller w.e. kudin a.p. parkinson phenotype in aged pink1 - deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration plos one 2009 4 e5777 10.1371 / journal.pone.0005777 19492057 77 .
stichel c.c. zhu x.r. bader v. linnartz b. schmidt s. lubbert h. mono - and double - mutant mouse models of parkinson 's disease display severe mitochondrial damage hum. mol. genet .
2007 16 2377 2393 10.1093 / hmg / ddm083 17412759 78 .
bonifati v. oostra b.a. heutink p. linking dj - 1 to neurodegeneration offers novel insights for understanding the pathogenesis of parkinson 's disease j. mol. med. ( berl . )
2004 82 163 174 10.1007 / s00109 - 003 - 0512 - 1 14712351 79 .
abou - sleiman p.m. healy d.g. wood n.w. causes of parkinson 's disease : genetics of dj - 1 cell tissue res .
2004 318 185 188 10.1007 / s00441 - 004 - 0922 - 6 15503154 80 .
zimprich a. biskup s. leitner p. lichtner p. farrer m. lincoln s. kachergus j. hulihan m. uitti r.j. calne d.b. mutations in lrrk2 cause autosomal - dominant parkinsonism with pleomorphic pathology neuron 2004 44 601 607 10.1016 / j.neuron.2004.11.005 15541309 81 .
paisan - ruiz c. jain s. evans e.w. gilks w.p. simon j. van der brug m. de munain a.l. aparicio s. gil a.m. khan n. cloning of the gene containing mutations that cause park8 - linked parkinson 's disease neuron 2004 44 595 600 10.1016 / j.neuron.2004.10.023 15541308 82 .
west a.b. moore d.j. choi c. andrabi s.a. li x. dikeman d. biskup s. zhang z. lim k.l. dawson v.l. parkinson 's disease - associated mutations in lrrk2 link enhanced gtp - binding and kinase activities to neuronal toxicity hum. mol. genet .
2007 16 223 232 10.1093 / hmg / ddl471 17200152 83 .
cookson m.r. the role of leucine - rich repeat kinase 2 ( lrrk2 ) in parkinson 's disease nat. rev. neurosci .
2010 11 791 797 10.1038 / nrn2935 21088684 84 .
west a.b. moore d.j. biskup s. bugayenko a. smith w.w. ross c.a. dawson v.l. dawson t.m. parkinson 's disease - associated mutations in leucine - rich repeat kinase 2 augment kinase activity proc. natl. acad. sci. usa 2005 102 16842 16847 10.1073 / pnas.0507360102 16269541 85 .
simon h.h. saueressig h. wurst w. goulding m.d. o'leary d.d. fate of midbrain dopaminergic neurons controlled by the engrailed genes j. neurosci .
2001 21 3126 3134 11312297 86 .
yu - chin su x.q. impairment of mitochondrial dynamics : a target for the treatment of neurological disorders ?
future med. 2013 8 333 346 87 .
tanner c.m. goldman s.m. epidemiology of parkinson 's disease neurol. clin .
1996 14 317 35 10.1016 / s0733 - 8619 ( 05 ) 70259 - 0 8827174 88 .
caradoc - davies t.h. weatherall m. dixon g.s. caradoc - davies g. hantz p. is the prevalence of parkinson 's disease in new zealand really changing ?
acta neurol. scand .
1992 86 40 44 10.1111 / j.1600 - 0404.1992.tb08051.x 1519473 89 .
morgante l. rocca w.a. di rosa a.e. de domenico p. grigoletto f. meneghini f. reggio a. savettieri g. castiglione m.g. patti f. prevalence of parkinson 's disease and other types of parkinsonism : a door - to - door survey in three sicilian municipalities .
the sicilian neuro - epidemiologic study ( snes ) group neurology 1992 42 1901 1907 1407570 90 .
mutch w.j. dingwall - fordyce i. downie a.w. paterson j.g. roy s.k. parkinson 's disease in a scottish city br. med. j. ( clin. res. ed . )
1986 292 534 536 10.1136 / bmj.292.6519.534 91 .
polymeropoulos m.h. higgins j.j. golbe l.i. johnson w.g. ide s.e. di iorio g. sanges g. stenroos e.s. pho l.t. schaffer a.a. mapping of a gene for parkinson 's disease to chromosome 4q21 - q23 science 1996 274 1197 1199 10.1126 / science.274.5290.1197 8895469 92 .
dekker m.c. bonifati v. van duijn c.m. parkinson 's disease : piecing together a genetic jigsaw brain 2003 126 1722 1733 10.1093 / brain / awg172 12805097 93 .
langston j.w. epidemiology versus genetics in parkinson 's disease : progress in resolving an age - old debate ann. neurol .
1998 44 suppl .
1 s45 s52 10.1002 / ana.410440707 9749572 94 .
bowers w.j. howard d.f. federoff h.j. gene therapeutic strategies for neuroprotection : implications for parkinson 's disease exp. neurol .
1997 144 58 68 10.1006 / exnr.1996.6389 9126153 95 .
kitada t. asakawa s. hattori n. matsumine h. yamamura y. minoshima s. yokochi m. mizuno y. shimizu n. mutations in the parkin gene cause autosomal recessive juvenile parkinsonism nature 1998 392 605 608 9560156 96 .
lincoln s. vaughan j. wood n. baker m. adamson j. gwinn - hardy k. lynch t. hardy j. farrer m. low frequency of pathogenic mutations in the ubiquitin carboxy - terminal hydrolase gene in familial parkinson 's disease neuroreport 1999 10 427 429 10.1097 / 00001756 - 199902050 - 00040 10203348 97 .
golbe l.i. di iorio g. bonavita v. miller d.c. duvoisin r.c. a large kindred with autosomal dominant parkinson 's disease ann. neurol .
1990 27 276 282 10.1002 / ana.410270309 2158268 98 .
kruger r. kuhn w. muller t. woitalla d. graeber m. kosel s. przuntek h. epplen j.t. schols l. riess o .
ala30pro mutation in the gene encoding alpha - synuclein in parkinson 's disease nat. genet .
1998 18 106 108 10.1038 / ng0298 - 106 9462735 99 .
polymeropoulos m.h. lavedan c. leroy e. ide s.e. dehejia a. dutra a. pike b. root h. rubenstein j. boyer r. mutation in the alpha - synuclein gene identified in families with parkinson 's disease science 1997 276 2045 2047 10.1126 / science.276.5321.2045 9197268 100 .
pham a.h. meng s. chu q.n. chan d.c. loss of mfn2 results in progressive , retrograde degeneration of dopaminergic neurons in the nigrostriatal circuit hum. mol. genet .
2012 21 4817 4826 10.1093 / hmg / dds311 22859504 101 .
lee s. sterky f.h. mourier a. terzioglu m. cullheim s. olson l. larsson n.g. mitofusin 2 is necessary for striatal axonal projections of midbrain dopamine neurons hum. mol. genet .
2012 21 4827 35 10.1093 / hmg / dds352 22914740 102 .
li h. chen y. jones a.f. sanger r.h. collis l.p. flannery r. mcnay e.c. yu t. schwarzenbacher r. bossy b. bcl - xl induces drp1 - dependent synapse formation in cultured hippocampal neurons proc. natl. acad. sci. usa 2008 105 2169 2174 10.1073 / pnas.0711647105 18250306 103 .
ishihara n. nomura m. jofuku a. kato h. suzuki s.o. masuda k. otera h. nakanishi y. nonaka i. goto y. mitochondrial fission factor drp1 is essential for embryonic development and synapse formation in mice nat. cell. biol .
2009 11 958 966 10.1038 / ncb1907 19578372 104 .
wakabayashi j. zhang z. wakabayashi n. tamura y. fukaya m. kensler t.w. iijima m. sesaki h. the dynamin - related gtpase drp1 is required for embryonic and brain development in mice j. cell biol .
2009 186 805 816 10.1083 / jcb.200903065 19752021 105 .
berthet a. margolis e.b. zhang j. hsieh i. zhang j. hnasko t.s. ahmad j. edwards r.h. sesaki h. huang e.j. loss of mitochondrial fission depletes axonal mitochondria in midbrain dopamine neurons j. neurosci .
2014 34 14304 14317 10.1523 / jneurosci.0930 - 14.2014 25339743 106 .
zarranz j.j. alegre j. gomez - esteban j.c. lezcano e. ros r. ampuero i. vidal l. hoenicka j. rodriguez o. atares b. the new mutation , e46k , of alpha - synuclein causes parkinson and lewy body dementia ann. neurol .
2004 55 164 173 10.1002 / ana.10795 14755719 107 .
bonifati v. rizzu p. squitieri f. krieger e. vanacore n. van swieten j.c. brice a. van duijn c.m. oostra b. meco g. dj - 1 ( park7 ) , a novel gene for autosomal recessive , early onset parkinsonism neurol. sci. 2003 24 159 160 10.1007 / s10072 - 003 - 0108 - 0 14598065 108 .
iwatsubo t. ito g. takatori s. hannno y. kuwahara t. pathogenesis of parkinson 's disease : implications from familial parkinson 's disease rinsho shinkeigaku 2005 45 899 901 16447757 109 .
bialecka m. hui s. klodowska - duda g. opala g. tan e.k. drozdzik m. analysis of lrrk 2 g 2019 s and i 2020 t mutations in parkinson 's disease neurosci. lett .
2005 390 1 3 10.1016 / j.neulet.2005.07.045 16115731 110 .
smith r.g. the aging process : where are the drug opportunities ?
curr. opin. chem. biol .
2000 4 371 376 10.1016 / s1367 - 5931 ( 00 ) 00104 - 6 10959763 111 .
le w. conneely o.m. he y. jankovic j. appel s.h. reduced nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to mptp - induced injury j. neurochem .
1999 73 2218 2221 10537083 112 .
xiao q. castillo s.o. nikodem v.m. distribution of messenger rnas for the orphan nuclear receptors nurr1 and nur77 ( ngfi - b ) in adult rat brain using in situ hybridization neuroscience 1996 75 221 230 10.1016 / 0306 - 4522 ( 96 ) 00159 - 5 8923536 113 .
rakovic a. grunewald a. seibler p. ramirez a. kock n. orolicki s. lohmann k. klein c. effect of endogenous mutant and wild - type pink1 on parkin in fibroblasts from parkinson disease patients hum. mol. genet .
2010 19 3124 3137 10.1093 / hmg / ddq215 20508036 114 .
rakovic a. grunewald a. kottwitz j. bruggemann n. pramstaller p.p. lohmann k. klein c. mutations in pink1 and parkin impair ubiquitination of mitofusins in human fibroblasts plos one 2011 6 e16746 10.1371 / journal.pone.0016746 21408142 115 .
jin h.j. li c.g. tanshinone iia and cryptotanshinone prevent mitochondrial dysfunction in hypoxia - induced h9c2 cells : association to mitochondrial ros , intracellular nitric oxide , and calcium levels evid .
based complement. alternat. med. 2013 2013 610694 10.1155 / 2013 / 610694 23533503 116 .
poole a.c. thomas r.e. andrews l.a. mcbride h.m. whitworth a.j. pallanck l.j. the pink1 / parkin pathway regulates mitochondrial morphology proc. natl. acad. sci. usa 2008 105 1638 1643 10.1073 / pnas.0709336105 18230723 117 .
yang y. ouyang y. yang l. beal m.f. mcquibban a. vogel h. lu b .
pink1 regulates mitochondrial dynamics through interaction with the fission / fusion machinery proc. natl. acad. sci. usa 2008 105 7070 7075 10.1073 / pnas.0711845105 18443288 118 .
yu w. sun y. guo s. lu b. the pink1 / parkin pathway regulates mitochondrial dynamics and function in mammalian hippocampal and dopaminergic neurons hum. mol. genet .
2011 20 3227 3240 10.1093 / hmg / ddr235 21613270 119 .
wang x. petrie t.g. liu y. liu j. fujioka h. zhu x. parkinson 's disease - associated dj - 1 mutations impair mitochondrial dynamics and cause mitochondrial dysfunction j. neurochem .
2012 121 830 839 10.1111 / j.1471 - 4159.2012.07734.x 22428580 120 .
ryan b.j. hoek s. fon e.a. wade - martins r. mitochondrial dysfunction and mitophagy in parkinson 's : from familial to sporadic disease trends biochem. sci. 2015 40 200 210 10.1016 / j.tibs.2015.02.003 25757399 121 .
niu j. yu m. wang c. xu z. leucine - rich repeat kinase 2 disturbs mitochondrial dynamics via dynamin - like protein j. neurochem .
2012 122 650 658 10.1111 / j.1471 - 4159.2012.07809.x 22639965 122 .
wang x. yan m.h. fujioka h. liu j. wilson - delfosse a. chen s.g. perry g. casadesus g. zhu x .
lrrk2 regulates mitochondrial dynamics and function through direct interaction with dlp1 hum. mol. genet .
2012 21 1931 1944 10.1093 / hmg / dds003 22228096 123 .
su y.c. qi x. inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by lrrk2 g2019s mutation hum. mol. genet .
2013 22 4545 4561 10.1093 / hmg / ddt301 23813973 124 .
guo x. disatnik m.h. monbureau m. shamloo m. mochly - rosen d. qi x. inhibition of mitochondrial fragmentation diminishes huntington 's disease - associated neurodegeneration j. clin. investig .
2013 123 5371 5388 10.1172 / jci70911 24231356 125 .
qi x. qvit n. su y.c. mochly - rosen d. a novel drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity j. cell sci. 2013 126 789 802 10.1242 / jcs.114439 23239023 126 .
yamamoto a. yue z. autophagy and its normal and pathogenic states in the brain annu. rev. neurosci .
2014 37 55 78 10.1146 / annurev - neuro - 071013 - 014149 24821313 127 .
redmann m. dodson m. boyer - guittaut m. darley - usmar v. zhang j. mitophagy mechanisms and role in human diseases int. j. biochem .
cell biol .
2014 53 127 33 10.1016 / j.biocel.2014.05.010 24842106 128 .
fass e. amar n. elazar z. identification of essential residues for the c - terminal cleavage of the mammalian lc3 : a lesson from yeast atg8 autophagy 2007 3 48 50 10.4161 / auto.3417 17102583 129 .
kabeya y. mizushima n. ueno t. yamamoto a. kirisako t. noda t. kominami e. ohsumi y. yoshimori t .
lc3 , a mammalian homologue of yeast apg8p , is localized in autophagosome membranes after processing embo j .
2000 19 5720 5728 10.1093 / emboj / 19.21.5720 11060023 130 .
kanki t. wang k. cao y. baba m. klionsky d.j .
atg32 is a mitochondrial protein that confers selectivity during mitophagy dev .
cell 2009 17 98 109 10.1016 / j.devcel.2009.06.014 19619495 131 .
okamoto k. kondo - okamoto n. ohsumi y. mitochondria - anchored receptor atg32 mediates degradation of mitochondria via selective autophagy dev .
cell 2009 17 87 97 10.1016 / j.devcel.2009.06.013 19619494 132 .
liu l. feng d. chen g. chen m. zheng q. song p. ma q. zhu c. wang r. qi w. mitochondrial outer - membrane protein fundc1 mediates hypoxia - induced mitophagy in mammalian cells nat. cell biol .
2012 14 177 185 10.1038 / ncb2422 22267086 133 .
narendra d. kane l.a. hauser d.n. fearnley i.m. youle r.j .
p62 / sqstm1 is required for parkin - induced mitochondrial clustering but not mitophagy ; vdac1 is dispensable for both autophagy 2010 6 1090 1106 10.4161 / auto.6.8.13426 20890124 134 .
shi r.y. zhu s.h. li v. gibson s.b. xu x.s. kong j.m .
bnip3 interacting with lc3 triggers excessive mitophagy in delayed neuronal death in stroke cns neurosci. ther .
2014 20 1045 1055 10.1111 / cns.12325 25230377 135 .
strappazzon f. nazio f. corrado m. cianfanelli v. romagnoli a. fimia g.m. campello s. nardacci r. piacentini m. campanella m .
ambra1 is able to induce mitophagy via lc3 binding , regardless of parkin and p62 / sqstm1 cell .
death differ .
2015 22 419 432 10.1038 / cdd.2014.139 25215947 136 .
johansen t. lamark t. selective autophagy mediated by autophagic adapter proteins autophagy 2011 7 279 296 10.4161 / auto.7.3.14487 21189453 137 .
wu f. xu h.d. guan j.j. hou y.s. gu j.h. zhen x.c. qin z.h. rotenone impairs autophagic flux and lysosomal functions in parkinson 's disease neuroscience 2015 284 900 911 10.1016 / j.neuroscience.2014.11.004 25446361 138 .
arsikin k. kravic - stevovic t. jovanovic m. ristic b. tovilovic g. zogovic n. bumbasirevic v. trajkovic v. harhaji - trajkovic l. autophagy - dependent and - independent involvement of amp - activated protein kinase in 6 - hydroxydopamine toxicity to sh - sy5y neuroblastoma cells biochim. biophys .
acta 2012 1822 1826 1836 10.1016 / j.bbadis.2012.08.006 22917563 139 .
youle r.j. narendra d.p. mechanisms of mitophagy nat. rev. mol .
cell biol .
2011 12 9 14 10.1038 / nrm3028 21179058 140 .
narendra d.p. youle r.j. targeting mitochondrial dysfunction : role for pink1 and parkin in mitochondrial quality control antioxid .
redox signal .
2011 14 1929 1938 10.1089 / ars.2010.3799 21194381 141 .
ashrafi g. schlehe j.s. lavoie m.j. schwarz t.l. mitophagy of damaged mitochondria occurs locally in distal neuronal axons and requires pink1 and parkin j. cell biol .
2014 206 655 670 10.1083 / jcb.201401070 25154397 142 .
geisler s. holmstrom k.m. skujat d. fiesel f.c. rothfuss o.c. kahle p.j. springer w .
pink1 / parkin - mediated mitophagy is dependent on vdac1 and p62 / sqstm1 nat. cell biol .
2010 12 119 131 10.1038 / ncb2012 20098416 143 .
rakovic a. shurkewitsch k. seibler p. grunewald a. zanon a. hagenah j. krainc d. klein c. phosphatase and tensin homolog ( pten ) - induced putative kinase 1 ( pink1 ) - dependent ubiquitination of endogenous parkin attenuates mitophagy : study in human primary fibroblasts and induced pluripotent stem cell - derived neurons j. biol. chem .
2013 288 2223 2237 10.1074 / jbc.m112.391680 23212910 144 .
mccoy m.k. cookson m.r. dj - 1 regulation of mitochondrial function and autophagy through oxidative stress autophagy 2011 7 531 532 10.4161 / auto.7.5.14684 21317550 145 .
thomas k.j. mccoy m.k. blackinton j. beilina a. van der brug m. sandebring a. miller d. maric d. cedazo - minguez a. cookson m.r. dj - 1 acts in parallel to the pink1 / parkin pathway to control mitochondrial function and autophagy hum. mol. genet .
2011 20 40 50 10.1093 / hmg / ddq430 20940149 146 .
irrcher i. aleyasin h. seifert e.l. hewitt s.j. chhabra s. phillips m. lutz a.k. rousseaux m.w. bevilacqua l. jahani - asl a. loss of the parkinson 's disease - linked gene dj - 1 perturbs mitochondrial dynamics hum. mol. genet .
2010 19 3734 46 10.1093 / hmg / ddq288 20639397 147 .
tang b. xiong h. sun p. zhang y. wang d. hu z. zhu z. ma h. pan q. xia j.h. association of pink1 and dj - 1 confers digenic inheritance of early - onset parkinson 's disease hum. mol. genet .
2006 15 1816 1825 10.1093 / hmg / ddl104 16632486 148 .
xiong h. wang d. chen l. choo y.s. ma h. tang c. xia k. jiang w. ronai z. zhuang x. parkin , pink1 , and dj - 1 form a ubiquitin e3 ligase complex promoting unfolded protein degradation j. clin. investig .
2009 119 650 660 10.1172 / jci37617 19229105 149 .
plowey e.d. cherra s.j .
3rd liu y.j. chu c.t. role of autophagy in g2019s - lrrk2 - associated neurite shortening in differentiated sh - sy5y cells j. neurochem .
2008 105 1048 1056 10.1111 / j.1471 - 4159.2008.05217.x 18182054 150 .
yakhine - diop s.m. bravo - san pedro j.m. gomez - sanchez r. pizarro - estrella e. rodriguez - arribas m. climent v. aiastui a. lopez de munain a. fuentes j.m. gonzalez - polo r.a .
g2019s lrrk2 mutant fibroblasts from parkinson 's disease patients show increased sensitivity to neurotoxin 1 - methyl - 4 - phenylpyridinium dependent of autophagy toxicology 2014 324 1 9 10.1016 / j.tox.2014.07.001 25017139 151 .
sanchez - danes a. richaud - patin y. carballo - carbajal i. jimenez - delgado s. caig c. mora s. di guglielmo c. ezquerra m. patel b. giralt a. disease - specific phenotypes in dopamine neurons from human ips - based models of genetic and sporadic parkinson 's disease embo mol. med. 2012 4 380 395 10.1002 / emmm.201200215 22407749 152 .
lachenmayer m.l. yue z. genetic animal models for evaluating the role of autophagy in etiopathogenesis of parkinson disease autophagy 2012 8 1837 1838 10.4161 / auto.21859 22931754 153 .
alegre - abarrategui j. christian h. lufino m.m. mutihac r. venda l.l. ansorge o. wade - martins r .
lrrk2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model hum. mol. genet .
2009 18 4022 4034 10.1093 / hmg / ddp346 19640926 154 .
saez - atienzar s. bonet - ponce l. blesa j.r. romero f.j. murphy m.p. jordan j. galindo m.f. the lrrk2 inhibitor gsk2578215a induces protective autophagy in sh - sy5y cells : involvement of drp - 1 - mediated mitochondrial fission and mitochondrial - derived ros signaling cell death dis .
2014 5 e1368 10.1038 / cddis.2014.320 25118928 155 .
gomez - suaga p. luzon - toro b. churamani d. zhang l. bloor - young d. patel s. woodman p.g. churchill g.c. hilfiker s. leucine - rich repeat kinase 2 regulates autophagy through a calcium - dependent pathway involving naadp hum. mol. genet .
2012 21 511 525 10.1093 / hmg / ddr481 22012985 156 .
bravo - san pedro j.m. niso - santano m. gomez - sanchez r. pizarro - estrella e. aiastui - pujana a. gorostidi a. climent v. lopez de maturana r. sanchez - pernaute r. lopez de munain a. the lrrk2 g2019s mutant exacerbates basal autophagy through activation of the mek / erk pathway cell. mol .
life sci. 2013 70 121 136 10.1007 / s00018 - 012 - 1061 - y 22773119 157 .
gomez - suaga p. hilfiker s .
lrrk2 as a modulator of lysosomal calcium homeostasis with downstream effects on autophagy autophagy 2012 8 692 693 10.4161 / auto.19305 22441017 158 .
orenstein s.j. kuo s.h. tasset i. arias e. koga h. fernandez - carasa i. cortes e. honig l.s. dauer w. consiglio a. interplay of lrrk2 with chaperone - mediated autophagy nat. neurosci .
2013 16 394 406 10.1038 / nn.3350 23455607 159 .
su y.c. guo x. qi x. threonine 56 phosphorylation of bcl - 2 is required for lrrk2 g2019s - induced mitochondrial depolarization and autophagy biochim. biophys .
acta 2015 1852 12 21 10.1016 / j.bbadis.2014.11.009 25446991 160 .
ramsay r.r. salach j.i. singer t.p. uptake of the neurotoxin 1 - methyl - 4 - phenylpyridine ( mpp +) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of nad + - linked substrates by mpp + biochem. biophys. res. commun .
1986 134 743 748 10.1016 / s0006 - 291x ( 86 ) 80483 - 1 2868716 161 .
marey - semper i. gelman m. levi - strauss m. the high sensitivity to rotenone of striatal dopamine uptake suggests the existence of a constitutive metabolic deficiency in dopaminergic neurons from the substantia nigra eur. j. neurosci .
1993 5 1029 1034 10.1111 / j.1460 - 9568.1993.tb00955.x 7904221 162 .
chinta s.j. mallajosyula j.k. rane a. andersen j.k. mitochondrial alpha - synuclein accumulation impairs complex i function in dopaminergic neurons and results in increased mitophagy in vivo neurosci. lett .
2010 486 235 239 10.1016 / j.neulet.2010.09.061 20887775 163 .
devi l. raghavendran v. prabhu b.m. avadhani n.g. anandatheerthavarada h.k. mitochondrial import and accumulation of alpha - synuclein impair complex i in human dopaminergic neuronal cultures and parkinson disease brain j. biol. chem .
2008 283 9089 9100 10.1074 / jbc.m710012200 18245082 164 .
martin l.j. pan y. price a.c. sterling w. copeland n.g. jenkins n.a. price d.l. lee m.k. parkinson 's disease alpha - synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death j. neurosci .
2006 26 41 50 10.1523 / jneurosci.4308 - 05.2006 16399671 165 .
zuo l. motherwell m.s. the impact of reactive oxygen species and genetic mitochondrial mutations in parkinson 's disease gene 2013 532 18 23 10.1016 / j.gene.2013.07.085 23954870 166 .
nakamura t. prikhodko o.a. pirie e. nagar s. akhtar m.w. oh c.k. mckercher s.r. ambasudhan r. okamoto s.i. lipton s.a. aberrant protein s - nitrosylation contributes to the pathophysiology of neurodegenerative diseases neurobiol. dis .
2015 10.1016 / j.nbd.2015.03.017 25796565 167 .
van muiswinkel f.l. steinbusch h.w. drukarch b. de vente j. identification of no - producing and - receptive cells in mesencephalic transplants in a rat model of parkinson 's disease : a study using nadph - d enzyme - and nosc / cgmp immunocytochemistry ann. n. y. acad. sci. 1994 738 289 304 10.1111 / j.1749 - 6632.1994.tb21815.x 7530418 168 .
gu z. nakamura t. lipton s.a. redox reactions induced by nitrosative stress mediate protein misfolding and mitochondrial dysfunction in neurodegenerative diseases mol. neurobiol .
2010 41 55 72 10.1007 / s12035 - 010 - 8113 - 9 20333559 169 .
levecque c. elbaz a. clavel j. richard f. vidal j.s. amouyel p. tzourio c. alperovitch a. chartier - harlin m.c. association between parkinson 's disease and polymorphisms in the nnos and inos genes in a community - based case - control study hum. mol. genet .
2003 12 79 86 10.1093 / hmg / ddg009 12490535 170 .
joniec i. ciesielska a. kurkowska - jastrzebska i. przybylkowski a. czlonkowska a. czlonkowski a. age - and sex - differences in the nitric oxide synthase expression and dopamine concentration in the murine model of parkinson 's disease induced by 1 - methyl - 4 - phenyl - 1,2,3,6 - tetrahydropyridine brain res .
2009 1261 7 19 10.1016 / j.brainres.2008.12.081 19401171 171 .
watanabe y. kato h. araki t. protective action of neuronal nitric oxide synthase inhibitor in the mptp mouse model of parkinson 's disease metab .
brain dis .
2008 23 51 69 10.1007 / s11011 - 007 - 9080 - 3 18030609 172 .
castagnoli k. palmer s. castagnoli n. jr. neuroprotection by ( r ) - deprenyl and 7 - nitroindazole in the mptp c57bl / 6 mouse model of neurotoxicity neurobiology ( bp ) 1999 7 135 149 10591048 173 .
dolezal p. likic v. tachezy j. lithgow t. evolution of the molecular machines for protein import into mitochondria science 2006 313 314 318 10.1126 / science.1127895 16857931 174 .
de marcos - lousa c. sideris d.p. tokatlidis k. translocation of mitochondrial inner - membrane proteins : conformation matters trends biochem. sci. 2006 31 259 267 10.1016 / j.tibs.2006.03.006 16616497 175 .
baker m.j. frazier a.e. gulbis j.m. ryan m.t. mitochondrial protein - import machinery : correlating structure with function trends cell. biol .
2007 17 456 464 10.1016 / j.tcb.2007.07.010 17825565 176 .
gottschalk w.k. lutz m.w. he y.t. saunders a.m. burns d.k. roses a.d. chiba - falek o. the broad impact of tom40 on neurodegenerative diseases in aging j. parkinsons dis .
alzheimers dis .
2014 1 12 25745640 177 .
bender a. desplats p. spencer b. rockenstein e. adame a. elstner m. laub c. mueller s. koob a.o. mante m .
tom40 mediates mitochondrial dysfunction induced by alpha - synuclein accumulation in parkinson 's disease plos one 2013 8 e62277 10.1371 / journal.pone.0062277 23626796 178 .
okatsu k. kimura m. oka t. tanaka k. matsuda n. unconventional pink1 localization to the outer membrane of depolarized mitochondria drives parkin recruitment j. cell sci. 2015 128 964 978 10.1242 / jcs.161000 25609704 179 .
kato h. lu q. rapaport d. kozjak - pavlovic v .
tom70 is essential for pink1 import into mitochondria plos one 2013 8 e58435 10.1371 / journal.pone.0058435 23472196 180 .
cooper o. seo h. andrabi s. guardia - laguarta c. graziotto j. sundberg m. mclean j.r. carrillo - reid l. xie z. osborn t. pharmacological rescue of mitochondrial deficits in ipsc - derived neural cells from patients with familial parkinson 's disease sci. transl. med. 2012 4 141ra90 10.1126 / scitranslmed.3003985 22764206 181 .
reinhardt p. schmid b. burbulla l.f. schondorf d.c. wagner l. glatza m. hoing s. hargus g. heck s.a. dhingra a. genetic correction of a lrrk2 mutation in human ipscs links parkinsonian neurodegeneration to erk - dependent changes in gene expression cell .
stem cell .
2013 12 354 367 10.1016 / j.stem.2013.01.008 23472874 182 .
toyoda y. erkut c. pan - montojo f. boland s. stewart m.p. muller d.j. wurst w. hyman a.a. kurzchalia t.v. products of the parkinson 's disease - related glyoxalase dj - 1 , d - lactate and glycolate , support mitochondrial membrane potential and neuronal survival biol .
open 2014 3 777 784 10.1242 / bio.20149399 25063200 183 .
daher j.p. abdelmotilib h.a. hu x. volpicelli - daley l.a. moehle m.s. fraser k.b. needle e. chen y. steyn s.j. galatsis p .
lrrk2 pharmacological inhibition abates alpha - synuclein induced neurodegeneration j. biol. chem .
2015 290 19433 19444 10.1074 / jbc.m115.660001 26078453 184 .
li t. he x. thomas j.m. yang d. zhong s. xue f. smith w.w. a novel gtp - binding inhibitor , fx2149 , attenuates lrrk2 toxicity in parkinson 's disease models plos one 2015 10 e0122461 10.1371 / journal.pone.0122461 25816252 185 .
chiu c.c. yeh t.h. lai s.c. wu - chou y.h. chen c.h. mochly - rosen d. huang y.c. chen y.j. chen c.l. chang y.m. neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone - induced cellular and animal models of parkinsonism exp. neurol .
2015 263 244 253 10.1016 / j.expneurol.2014.09.016 25263579 186 .
richter f. gao f. medvedeva v. lee p. bove n. fleming s.m. michaud m. lemesre v. patassini s. de la rosa k. chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha - synuclein overexpression in nigrostriatal dopaminergic neurons neurobiol. dis .
2014 69 263 275 10.1016 / j.nbd.2014.05.012 24844147 187 .
rappold p.m. cui m. grima j.c. fan r.z. de mesy - bentley k.l. chen l. zhuang x. bowers w.j. tieu k .
drp1 inhibition attenuates neurotoxicity and dopamine release deficits in vivo nat. commun .
2014 5 5244 10.1038 / ncomms6244 25370169 188 .
mena n.p. garcia - beltran o. lourido f. urrutia p.j. mena r. castro - castillo v. cassels b.k. nunez m.t. the novel mitochondrial iron chelator 5 - (( methylamino ) methyl ) - 8 - hydroxyquinoline protects against mitochondrial - induced oxidative damage and neuronal death biochem. biophys. res. commun .
2015 463 787 792 10.1016 / j.bbrc.2015.06.014 26051278 189 .
jiang j. zuo y. gu z. rapamycin protects the mitochondria against oxidative stress and apoptosis in a rat model of parkinson 's disease int. j. mol. med. 2013 31 825 832 23426728 190 .
xiong n. xiong j. khare g. chen c. huang j. zhao y. zhang z. qiao x. feng y. reesaul h. edaravone guards dopamine neurons in a rotenone model for parkinson 's disease plos one 2011 6 e20677 10.1371 / journal.pone.0020677 21677777 191 .
dabbeni - sala f. di santo s. franceschini d. skaper s.d. giusti p. melatonin protects against 6 - ohda - induced neurotoxicity in rats : a role for mitochondrial complex i activity faseb j .
2001 15 164 170 10.1096 / fj.00 - 0129com 11149904 192 .
zaitone s.a. hammad l.n. farag n.e. antioxidant potential of melatonin enhances the response to l - dopa in 1 - methyl 4 - phenyl 1,2,3,6 - tetrahydropyridine - parkinsonian mice pharmacol. rep .
2013 65 1213 1226 10.1016 / s1734 - 1140 ( 13 ) 71479 - 8 24399717 193 .
karuppagounder s.s. madathil s.k. pandey m. haobam r. rajamma u. mohanakumar k.p. quercetin up - regulates mitochondrial complex - i activity to protect against programmed cell death in rotenone model of parkinson 's disease in rats neuroscience 2013 236 136 148 10.1016 / j.neuroscience.2013.01.032 23357119 194 .
jayaraj r.l. elangovan n. dhanalakshmi c. manivasagam t. essa m.m. cnb - 001 , a novel pyrazole derivative mitigates motor impairments associated with neurodegeneration via suppression of neuroinflammatory and apoptotic response in experimental parkinson 's disease mice chem. biol. interact .
2014 220 149 157 10.1016 / j.cbi.2014.06.022 24995576 195 .
abdin a.a. sarhan n.i. intervention of mitochondrial dysfunction - oxidative stress - dependent apoptosis as a possible neuroprotective mechanism of alpha - lipoic acid against rotenone - induced parkinsonism and l - dopa toxicity neurosci. res .
2011 71 387 395 10.1016 / j.neures.2011.08.008 21889550 196 .
kaur h. chauhan s. sandhir r. protective effect of lycopene on oxidative stress and cognitive decline in rotenone induced model of parkinson 's disease neurochem. res .
2011 36 1435 1443 10.1007 / s11064 - 011 - 0469 - 3 21484267 197 .
chen c.h. budas g.r. churchill e.n. disatnik m.h. hurley t.d. mochly - rosen d. activation of aldehyde dehydrogenase - 2 reduces ischemic damage to the heart science 2008 321 1493 1145 10.1126 / science.1158554 18787169 198 .
bordet t. buisson b. michaud m. drouot c. galea p. delaage p. akentieva n.p. evers a.s. covey d.f. ostuni m.a. identification and characterization of cholest - 4 - en - 3 - one , oxime ( tro19622 ) , a novel drug candidate for amyotrophic lateral sclerosis j. pharmacol. exp. ther .
2007 322 709 720 10.1124 / jpet.107.123000 17496168 199 .
gouarne c. tracz j. paoli m.g. deluca v. seimandi m. tardif g. xilouri m. stefanis l. bordet t. pruss r.m. protective role of olesoxime against wild - type alpha - synuclein - induced toxicity in human neuronally differentiated shsy - 5y cells br. j. pharmacol .
2015 172 235 245 10.1111 / bph.12939 25220617 200 .
fernandez - moriano c. gonzalez - burgos e. gomez - serranillos m.p. mitochondria - targeted protective compounds in parkinson 's and alzheimer 's diseases oxid. med. cell. longev .
2015 2015 408927 10.1155 / 2015 / 408927 26064418 201 .
valadas j.s. vos m. verstreken p. therapeutic strategies in parkinson 's disease : what we have learned from animal models ann. n. y. acad. sci. 2015 1338 16 37 10.1111 / nyas.12577 25515068 202 .
procaccio v. bris c. de la barca j.m.c. oca f. chevrollier a. amati - bonneau p. bonneau d. reynier p. perspectives of drug - based neuroprotection targeting mitochondria rev. neurol .
( paris ) 2014 170 390 400 10.1016 / j.neurol.2014.03.005 24792485 203 .
yadav a. agarwal s. tiwari s.k. chaturvedi r.k. mitochondria : prospective targets for neuroprotection in parkinson 's disease curr. pharm. des .
2014 20 5558 5573 10.2174 / 1381612820666140305224545 24606805